Vensica Secures $11M Funding to Advance Needle-Free Delivery of Botulinum Toxin A

Vensica Medical secures $11 million funding to advance a needle-free delivery system for botulinum toxin A (Xeomin®) to treat overactive bladder.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here